Zuhera Drug Interactions

Clinical Trials for Herceptin: No formal interaction studies have been performed with Herceptin in humans. Clinically significant interactions between Herceptin and the concomitant medication used in clinical trials have not been observed (see Pharmacology: Pharmacokinetics under Actions).
In studies where Herceptin was administered in combination with docetaxel, carboplatin, or anastrozole, pharmacokinetics of these medications was not altered nor was the pharmacokinetics of Trastuzumab altered.
Concentrations of paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-paclitaxel, POH, and doxorubicinol, DOL) were not altered in the presence of Trastuzumab. However, Trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this metabolite is unclear. No changes were observed in Trastuzumab concentrations in the presence of paclitaxel and doxorubicin.
The results of the drug interaction substudy evaluating the pharmacokinetics of capecitabine and cisplatin when used with or without Trastuzumab suggested that the exposure to the bioactive metabolites (e.g., 5‑FU) of capecitabine was not affected by concurrent use of cisplatin or by concurrent use of cisplatin with Trastuzumab. However, capecitabine itself showed higher concentrations and a longer half-life when combined with Trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use of capecitabine plus Trastuzumab.